PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 11, 2026Pharmaceutics0 citationsOpen Access

Impact of Oral Pre-Exposure Secretory IgA Prophylactic Produced in Rice on Gut Microbiome Homeostasis

View Full Paper
RBRavi BharadwajCGCarlos GasparTMTyler D. Moeller

Key Points

  • This research aims to evaluate the safety and impact of oral SIgA on the gut microbiome and its effectiveness against ETEC.
  • Developed secretory IgA (SIgA) in rice for oral administration.
  • Conducted in vitro comparisons of binding efficiency of rice-produced SIgA to CfaE.
  • Administered 68–90 SIgA to Aotus nancymaae and assessed gut microbiome changes.
  • Oral administration of SIgA did not alter gut microbiome distribution.
  • No signs of systemic exposure were observed following SIgA administration.
  • The findings suggest SIgA is stable and safe for use against ETEC.

Abstract

Background/Objectives: Enterotoxigenic Escherichia coli (ETEC) is a leading cause of diarrheal illness worldwide, resulting in approximately 380,000 deaths annually, with significant morbidity in children and travelers to endemic regions. ETEC infection begins with the attachment of the bacterium to the small intestine via filamentous colonization factors (CF), followed by the production of heat-labile (LT) and heat-stable (ST) toxins that induce watery diarrhea. Targeting CF to prevent ETEC attachment is challenging due to strain heterogeneity. Methods: In previous studies, we developed a class-switched human monoclonal antibody, 68–90, expressed as secretory IgA (SIgA) in rice for cost-effective and stable storage. Rice-produced SIgA exhibited comparable binding efficiency to CfaE, a component of CF, compared to CHO-produced SIgA in vitro. Results: In this work, we showed that oral administration of 68–90 SIgA to Aotus nancymaae did not alter gut microbiome distribution or show signs of systemic exposure. Conclusions: These findings suggest that oral delivery of ETEC-specific SIgA is safe and does not disrupt the gut microbial population, highlighting its potential as an effective and targeted therapeutic strategy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Bharadwaj et al. (2026) studied this question.

synapsesocial.com/papers/69d9e64e78050d08c1b76a5ahttps://doi.org/10.3390/pharmaceutics18040457
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases2022 · 39 citations
  2. 2Mathematical Modeling of Vedolizumab Treatment’s Effect on Microbiota and Intestinal Permeability in Inflammatory Bowel Disease Patients2024 · 5 citations
  3. 3Protection by Milk Immunoglobulin Concentrate against Oral Challenge with EnterotoxigenicEscherichia coli1988 · 294 citations
  4. 4Oral Passive Immunization With Plasma-Derived Polyreactive Secretory-Like IgA/M Partially Protects Mice Against Experimental Salmonellosis2018 · 12 citations
  5. 5Extensive impact of non-antibiotic drugs on human gut bacteria2018 · 1,985 citations